GS Paper III · Science & Technology · Biotechnology
🧬 Biotechnology — Methods, Applications & Challenges
Genetic Engineering · RDT & PCR · CRISPR-Cas9 · RNAi · Gene Therapy · CAR-T · GM Crops · BIRSA 101 Sickle Cell Therapy · Genome-Edited Rice · India's $137 Billion Bioeconomy · Govt Initiatives · Ethical Challenges
🔬
Methods in Biotechnology
Genetic Engineering · RDT · PCR · RNAi · Tissue Culture · Bioinformatics
📖 What is Biotechnology?
Biotechnology is the application of living organisms or their parts to make technological advances and utilise those technologies in various fields. The modern era began with the discovery of the DNA structure (Watson & Crick, 1953), the development of genetic engineering techniques, and the polymerase chain reaction (PCR). It has applications in medicine, agriculture, industry, and the environment.
📊 Legacy IAS — Recombinant DNA Technology (RDT) — Simplified Steps
🔄
PCR — Polymerase Chain Reaction
Unlike RDT (cloning inside living cell), PCR replicates DNA in vitro (outside the cell).
Uses short artificial DNA primers to select a genome segment.
Taq polymerase enzyme amplifies that segment in multiple cycles → millions of copies in hours.
Used for: diagnosis of infectious diseases (e.g., COVID-19 RT-PCR), forensics, paternity testing.
Uses short artificial DNA primers to select a genome segment.
Taq polymerase enzyme amplifies that segment in multiple cycles → millions of copies in hours.
Used for: diagnosis of infectious diseases (e.g., COVID-19 RT-PCR), forensics, paternity testing.
🔇
RNAi — RNA Interference
Natural defence mechanism of plants and eukaryotic cells.
Small RNA pieces silence genes by binding to mRNAs and blocking protein translation.
Used for: Investigating gene functions, knocking down disease genes, developing pest-resistant plants.
Think of it as a "mute button" for specific genes.
Small RNA pieces silence genes by binding to mRNAs and blocking protein translation.
Used for: Investigating gene functions, knocking down disease genes, developing pest-resistant plants.
Think of it as a "mute button" for specific genes.
🌱
Tissue Culture
Growing tissues/cells in artificial medium outside the parent organism.
Plant tissue culture exploits totipotency — any plant cell can grow into a full plant.
Used for: Propagating valuable plants, identifying infections, enzyme deficiencies, chromosomal anomalies, cancer classification, vaccine testing.
Plant tissue culture exploits totipotency — any plant cell can grow into a full plant.
Used for: Propagating valuable plants, identifying infections, enzyme deficiencies, chromosomal anomalies, cancer classification, vaccine testing.
💡 Bioinformatics — Where Biology Meets Computer Science
Bioinformatics uses mathematics, computer science, and biology to develop software tools for understanding large, complex biological data — like genome sequences and gene expression patterns. Its main application is in drug discovery and development. Think of it as "Google for genomes" — searching through billions of genetic data points to find meaningful patterns.
✂
CRISPR-Cas9 — The Gene Editing Revolution
Nobel Prize 2020 · Guide RNA · Cas9 Protein · Base Editing · Prime Editing
📖 What is CRISPR-Cas9?
CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a revolutionary gene-editing tool adapted from a natural defence mechanism that bacteria use against viruses. When a virus infects a bacterium, the bacterium stores a fragment of the viral DNA in its CRISPR locus — like a "mugshot file." If the virus attacks again, the bacterium produces guide RNA from this stored fragment, which directs the Cas9 protein (molecular scissors) to find and cut the invading viral DNA. Scientists repurposed this system to edit any gene in any organism. The 2020 Nobel Prize in Chemistry was awarded to Jennifer Doudna and Emmanuelle Charpentier for this discovery.
📊 Legacy IAS — How CRISPR-Cas9 Works
🎯
Beyond CRISPR — Next-Gen Editing
Base Editing: Changes one DNA letter to another without cutting both strands — like using a pencil eraser instead of scissors. More precise, fewer errors.
Prime Editing: Can insert, delete, or replace DNA without double-strand breaks — described as "search-and-replace for genomes."
TnpB (India's innovation): ICAR-CRRI Cuttack developed a compact gene-editing tool based on TnpB proteins — smaller than Cas9, easier to deliver into cells. Indian Patent
Prime Editing: Can insert, delete, or replace DNA without double-strand breaks — described as "search-and-replace for genomes."
TnpB (India's innovation): ICAR-CRRI Cuttack developed a compact gene-editing tool based on TnpB proteins — smaller than Cas9, easier to deliver into cells. Indian Patent
⚖
CRISPR — Key Ethical Issues
Germline editing: Changes to embryos are inherited by all future generations — scientific community deeply divided on whether this is justified.
He Jiankui scandal (2018): Chinese scientist edited human embryos (twin girls) — universally condemned, sentenced to prison.
Gene drives: Engineered traits that spread through wild populations — could eliminate disease-carrying mosquitoes but raises ecosystem concerns.
He Jiankui scandal (2018): Chinese scientist edited human embryos (twin girls) — universally condemned, sentenced to prison.
Gene drives: Engineered traits that spread through wild populations — could eliminate disease-carrying mosquitoes but raises ecosystem concerns.
🏏 Analogy — CRISPR = GPS + Scissors for DNA
Imagine DNA is a 30-volume encyclopedia with 3 billion letters. CRISPR is like having: (1) a GPS (the guide RNA) that can find the exact sentence you want in the entire encyclopedia, and (2) a pair of precise scissors (Cas9 protein) that cuts exactly at that sentence. You can then delete it, fix a typo in it, or insert a new sentence. Before CRISPR, editing DNA was like trying to find and fix a single typo in an encyclopedia while blindfolded. CRISPR made it as simple as "Find and Replace" in a Word document.
💊
Applications of Biotechnology
Red (Medical) · White (Industrial) · Green (Agricultural) · Environmental · Animal
| Colour Code | Field | Key Applications | Examples |
|---|---|---|---|
| 🔴 RED | Medical / Biopharma | Gene therapy, CAR-T cell therapy, genome sequencing, therapeutic proteins, diagnostics, vaccines | Humulin (insulin), Casgevy (CRISPR sickle cell cure), BIRSA 101, monoclonal antibodies, COVID vaccines |
| ⚪ WHITE | Industrial | Enzymes, biofuels, bio-based plastics, food processing, chemicals | S. cerevisiae (yeast) in beverages, microbial enzymes in detergents, bioethanol, biodiesel |
| 🟢 GREEN | Agricultural | GM crops, biopesticides, biofertilizers, genome-edited crops, precision agriculture | BT Cotton, genome-edited rice (Kamala, Pusa DST Rice 1), Golden Rice |
| 🔵 BLUE | Environmental | Bioremediation, biosensors, pollution control, renewable energy | Oil-spill cleanup microbes, plastic-degrading enzymes, biosensors for water quality |
| 🟣 ANIMAL | Animal Biotech | Transgenic animals, cloning, xenotransplantation | Dolly the sheep (first cloned mammal, 1996), GloFish, disease models |
🧬
Gene Therapy
Replaces a defective or missing gene with a healthier version inside a patient's cells. Can potentially cure genetic diseases with a single treatment. Casgevy (2023) was the first FDA-approved CRISPR gene therapy — cures sickle cell disease and beta-thalassemia. India launched BIRSA 101 (Nov 2025) — world's most affordable CRISPR therapy for sickle cell. Current Affairs
🛡
CAR-T Cell Therapy
A cancer immunotherapy where T cells are extracted, genetically modified in a lab to recognise cancer cells, then reinfused into the patient. India's NextCAR19 (by ImmunoACT) — approved by CDSCO — administered in 350+ patients across 70 hospitals by July 2025 at ~₹30 lakhs (vs ₹3–4 crore globally). India
🧠 Memory Aid — Colour-Coded Biotech
Red = Blood/Medicine (gene therapy, drugs). White = Clean/Industry (enzymes, biofuels). Green = Plants/Agriculture (GM crops, biopesticides). Blue = Water/Environment (bioremediation). Remember: "Red heals, White builds, Green grows, Blue cleans."
🇮🇳
Biotechnology in India — Bioeconomy & Institutions
$137 Billion Bioeconomy · 6,756 Startups · DBT · BIRAC · Biotech Parks
📖 India's Bioeconomy
India's bioeconomy grew from $35.5 billion (2014) to $137 billion (2022), contributing 4% to GDP and employing 2+ million people. India is among the top 12 biotech destinations globally and 3rd largest in Asia Pacific. Target: $300 billion by 2030. Biotech startups grew from 50 to over 6,756 in a decade (target: 10,000+).
| Subsector | Market Size | Share | Key Areas |
|---|---|---|---|
| Bio-Industrials | $58.97 bn | 43% | Industrial enzymes, biofuels, biogas, bio-plastics, detergent enzymes |
| Biopharma | $49.79 bn | 36% | Cancer immunotherapy, gene editing, biosimilars, biologics, precision medicine. India = world's largest supplier of low-cost medicines & vaccines. |
| Bio-Agriculture | $11.47 bn | 8% | BT Cotton, biopesticides, biofertilizers, genome-edited rice. India has 5th largest organic agriculture area. |
| Bio Research / BioIT | $9.28 bn | 7% | Clinical trials, contract research, drug discovery, biotech software, patent services |
| Covid Economy | $7.66 bn | 6% | COVID vaccines (Covishield, Covaxin), testing, related services |
🏛
Key Institutions
NBTB (1982): National Biotechnology Board — first body for biotech capability building.
DBT (1986): Department of Biotechnology — nodal agency under MoST. Supports R&D, innovation, manufacturing.
BIRAC: Biotechnology Industry Research Assistance Council — empowers biotech startups. Under DBT.
NCMR: National Centre for Microbial Resource — conserves India's microbial biodiversity.
IBDC: Indian Biological Data Centre — India's first national life science data repository. Follows FAIR principles.
DBT (1986): Department of Biotechnology — nodal agency under MoST. Supports R&D, innovation, manufacturing.
BIRAC: Biotechnology Industry Research Assistance Council — empowers biotech startups. Under DBT.
NCMR: National Centre for Microbial Resource — conserves India's microbial biodiversity.
IBDC: Indian Biological Data Centre — India's first national life science data repository. Follows FAIR principles.
📋
Government Initiatives
National Biopharma Mission: Industry-academia collaboration for biopharma development. Implemented by BIRAC.
Innovate in India (i3): Enable indigenous manufacturing + entrepreneurship.
Biotech-KISAN (2017): Connect science labs with farmers — innovative solutions at farm level.
Atal Jai Anusandhan Biotech Mission: Maternal & child health, AMR, vaccines, nutrition.
One Health Consortium (2021): Survey zoonotic and transboundary infections.
Biotech Parks: Technology incubation centres across India — translate research into products.
Innovate in India (i3): Enable indigenous manufacturing + entrepreneurship.
Biotech-KISAN (2017): Connect science labs with farmers — innovative solutions at farm level.
Atal Jai Anusandhan Biotech Mission: Maternal & child health, AMR, vaccines, nutrition.
One Health Consortium (2021): Survey zoonotic and transboundary infections.
Biotech Parks: Technology incubation centres across India — translate research into products.
📰
Current Affairs — Biotechnology (2024–2026)
BIRSA 101 · Genome-Edited Rice · TnpB Patent · Casgevy · Drug Rules Amendment
🇮🇳 BIRSA 101 — India's First Indigenous CRISPR Gene Therapy (Nov 2025) Critical
On November 20, 2025 (150th birth anniversary of Birsa Munda), India launched BIRSA 101 — the country's first indigenously developed CRISPR-Cas9 gene therapy for Sickle Cell Disease (SCD).
Developed by: CSIR-Institute of Genomics & Integrative Biology (CSIR-IGIB), Delhi.
Manufacturing partner: Serum Institute of India (SII) — for affordable, large-scale production.
Technology: Uses enFnCas9 (a novel Cas9 variant) to correct the sickle cell mutation directly.
Target population: 1.5–2 crore Indians affected, especially tribal communities in Chhattisgarh, Odisha, Jharkhand, Maharashtra, MP.
Cost advantage: Global CRISPR therapies like Casgevy cost ₹20–25 crore per patient. BIRSA 101 aims to be the world's most affordable CRISPR therapy.
Regulatory approval: Expected from CDSCO in 2026–2027.
National goal: "Sickle Cell-Free India by 2047."
Developed by: CSIR-Institute of Genomics & Integrative Biology (CSIR-IGIB), Delhi.
Manufacturing partner: Serum Institute of India (SII) — for affordable, large-scale production.
Technology: Uses enFnCas9 (a novel Cas9 variant) to correct the sickle cell mutation directly.
Target population: 1.5–2 crore Indians affected, especially tribal communities in Chhattisgarh, Odisha, Jharkhand, Maharashtra, MP.
Cost advantage: Global CRISPR therapies like Casgevy cost ₹20–25 crore per patient. BIRSA 101 aims to be the world's most affordable CRISPR therapy.
Regulatory approval: Expected from CDSCO in 2026–2027.
National goal: "Sickle Cell-Free India by 2047."
🌾
India's First Genome-Edited Rice (May 2025) Critical
India became the first country in the world to develop CRISPR-edited rice varieties:
1. DRR Rice 100 (Kamala) — derived from Samba Mahsuri. 19% higher grain yield, matures 20 days earlier, performs under low-fertilizer and drought conditions. Developed by ICAR-IIRR.
2. Pusa DST Rice 1 — developed by IARI. Enhanced drought and salinity tolerance.
Key: These are NOT GMOs — no foreign DNA inserted. Uses precise CRISPR edits within the plant's own genome. Exempted from strict GMO regulations under India's 2022 genome-editing guidelines.
1. DRR Rice 100 (Kamala) — derived from Samba Mahsuri. 19% higher grain yield, matures 20 days earlier, performs under low-fertilizer and drought conditions. Developed by ICAR-IIRR.
2. Pusa DST Rice 1 — developed by IARI. Enhanced drought and salinity tolerance.
Key: These are NOT GMOs — no foreign DNA inserted. Uses precise CRISPR edits within the plant's own genome. Exempted from strict GMO regulations under India's 2022 genome-editing guidelines.
🔧
TnpB Gene-Editing Tool — Indian Patent New
Scientists at ICAR-CRRI, Cuttack developed a gene-editing tool based on TnpB proteins — an evolutionary ancestor of CRISPR-Cas systems. TnpB is smaller, simpler, and easier to deliver into plant cells than Cas9 (~1300 amino acids). Secured an Indian patent. This reduces India's dependence on foreign CRISPR patents and IP. Demonstrated in rice and Arabidopsis.
💉
Casgevy — World's First CRISPR Drug (2023) Global
Casgevy (exagamglogene autotemcel), developed by CRISPR Therapeutics & Vertex, was approved in Dec 2023 — the first-ever CRISPR-based medicine. Cures sickle cell disease and beta-thalassemia by "turning on" fetal hemoglobin. Approved in USA, UK, EU, Canada, Saudi Arabia, UAE. By 2025, a CRISPR therapy also directly corrected a disease-causing mutation (for AATD-1) — first time this has been demonstrated.
📜
Drug Rules Amendment (Oct 2025) India
India's Ministry of Health amended the Drug Rules, 1945 (October 2025) — bringing all cell and gene therapy products under direct control of the DCGI (Drug Controller General of India). This covers manufacturing, import, GMP compliance, and regulatory approval of gene therapy, stem cell products, and xenografts. First comprehensive regulatory framework for these therapies in India.
📊 More Key Developments
NextCAR19 (India's CAR-T): India's first indigenous CAR-T therapy by ImmunoACT — CDSCO approved. 350+ patients treated across 70 hospitals by July 2025 at ~₹30 lakhs. Quartemi (for non-Hodgkin B-CLL) also launched.
CrisprBits (Jan 2025): Opened a gene-editing and diagnostics centre in Bengaluru — enhancing CRISPR R&D for rare diseases, AMR, and hospital infections.
CRISPR market: Projected to grow from $2.87 billion (2025) to $12.22 billion by 2035 (CAGR 15.6%). Asia Pacific is the fastest-growing market.
AI + CRISPR: AI is now used to design better guide RNAs, predict off-target effects, and discover new CRISPR systems — making gene editing more precise and safe.
CrisprBits (Jan 2025): Opened a gene-editing and diagnostics centre in Bengaluru — enhancing CRISPR R&D for rare diseases, AMR, and hospital infections.
CRISPR market: Projected to grow from $2.87 billion (2025) to $12.22 billion by 2035 (CAGR 15.6%). Asia Pacific is the fastest-growing market.
AI + CRISPR: AI is now used to design better guide RNAs, predict off-target effects, and discover new CRISPR systems — making gene editing more precise and safe.
⚠
Challenges in Biotechnology
Ethical · IP · Environmental · Biosecurity · Regulatory
⚖
Ownership & Equitable Access
Patents protect biotech innovations but can prevent developing countries from benefiting. CRISPR patents are split across international institutions — Indian organisations must navigate costly licensing. Casgevy costs ₹20–25 crore/patient — inaccessible to most. cDNA can be patented, raising concerns about "owning" genetic information.
🧪
Ethical Concerns
Germline editing: Changes heritable across generations — "playing God." He Jiankui affair (2018): Edited human embryos without consent → prison. Designer babies: Could be used for non-medical "enhancements." Dual use: Synthetic biology could create biological weapons. Liver toxicity concerns in gene therapy trials (Intellia paused trials, Oct 2025).
🌿
Environmental Impact
GM crops can affect non-target species and pollinators. Gene drives could unintentionally affect related species — e.g., drives targeting Palmer amaranth could harm Amaranthus species cultivated in India/Mexico/China. Uncertainty: Long-term effects of releasing gene-edited organisms are unknown.
📜
Practice MCQs — Biotechnology
UPSC Prelims · GS Paper III · Gene Editing · Biotech Applications
🎯 Practice MCQs — Test Your Understanding (Click to Answer)
Q1. BIRSA 101, launched in November 2025, is:
(Select the correct statement)
(Select the correct statement)
- (a) India's first genetically modified rice variety developed using Bt gene technology
- (b) A mRNA vaccine for sickle cell disease developed by Bharat Biotech
- (c) India's first indigenous CRISPR-Cas9 gene therapy for sickle cell disease, developed by CSIR-IGIB and manufactured by Serum Institute
- (d) A biofertilizer developed under the Biotech-KISAN programme for tribal farmers
✅ (c). BIRSA 101 is India's first indigenously developed CRISPR-based gene therapy for Sickle Cell Disease. Named after tribal icon Birsa Munda (150th birth anniversary). Developed by CSIR-IGIB using enFnCas9, with technology transferred to Serum Institute of India for affordable mass production. It targets the 1.5–2 crore Indians affected, especially tribal communities. CDSCO approval expected 2026–27. Goal: Sickle Cell-Free India by 2047.
Q2. India became the first country in the world to develop genome-edited rice varieties in May 2025. Which of the following is correct about these varieties?
- (a) They contain foreign DNA from drought-resistant wild grasses, making them GM crops subject to strict GMO regulations
- (b) They were edited using CRISPR-Cas9 without inserting foreign DNA, and are exempt from strict GMO regulations under India's 2022 genome-editing guidelines
- (c) They were developed using traditional hybridisation techniques and branded as "genome-edited" for marketing purposes
- (d) They were developed by Monsanto India under a technology-transfer agreement with ICAR
✅ (b). The two varieties — DRR Rice 100 (Kamala) and Pusa DST Rice 1 — were developed by ICAR using CRISPR-Cas9 to edit genes within the rice plant's own genome. No foreign DNA was inserted, which is the key distinction from traditional GM crops (like Bt Cotton which contains a bacterial gene). India's 2022 guidelines specifically exempted genome-edited plants (Site Directed Nuclease-1 and SDN-2 categories, where no foreign DNA is present) from the strict approval process that applies to GMOs. This is a crucial UPSC distinction: genome-edited ≠ genetically modified when no foreign DNA is involved.
Q3. Consider the following statements about CRISPR-Cas9:
1. It was adapted from a natural defence mechanism bacteria use against viruses.
2. The Cas9 protein acts as molecular scissors, while the guide RNA directs it to the target DNA.
3. The 2020 Nobel Prize in Chemistry was awarded for its discovery.
4. It can only be used on plant genomes, not on human or animal cells.
Which of the above statements are correct?
1. It was adapted from a natural defence mechanism bacteria use against viruses.
2. The Cas9 protein acts as molecular scissors, while the guide RNA directs it to the target DNA.
3. The 2020 Nobel Prize in Chemistry was awarded for its discovery.
4. It can only be used on plant genomes, not on human or animal cells.
Which of the above statements are correct?
- (a) 1, 2 and 3 only
- (b) 1 and 2 only
- (c) 2, 3 and 4
- (d) 1, 2, 3 and 4
✅ (a) 1, 2 and 3 only. Statement 4 is WRONG — CRISPR works on virtually any organism: bacteria, plants, animals, and humans. Casgevy (approved 2023) is a CRISPR therapy used on human blood cells. It has been used in clinical trials for sickle cell disease, cancer, heart disease, blindness, and more. Statements 1, 2, and 3 are all correct. The 2020 Nobel in Chemistry was awarded to Jennifer Doudna and Emmanuelle Charpentier.
Q4. Match the following biotechnology colour codes:
1. Red Biotechnology — Industrial applications
2. White Biotechnology — Medical/Pharmaceutical
3. Green Biotechnology — Agricultural
Which pairing(s) is/are correct?
1. Red Biotechnology — Industrial applications
2. White Biotechnology — Medical/Pharmaceutical
3. Green Biotechnology — Agricultural
Which pairing(s) is/are correct?
- (a) 1 and 2 only
- (b) 1, 2 and 3
- (c) 3 only
- (d) 2 and 3 only
✅ (c) 3 only. Pairing 1 is WRONG — Red = Medical (not Industrial). Pairing 2 is WRONG — White = Industrial (not Medical). Pairing 3 is correct — Green = Agricultural. This is a classic swap trap in UPSC. Remember: "Red heals, White builds, Green grows." Red = blood/health. White = clean/industry. Green = plants/agriculture.
Q5. In October 2025, India amended the Drug Rules, 1945, to bring which of the following under DCGI control for the first time?
- (a) All Ayurvedic and herbal medicines sold online
- (b) Over-the-counter COVID-19 rapid antigen test kits
- (c) Genetically modified food products in retail stores
- (d) Cell and gene therapy products, including stem cell products and xenografts
✅ (d). The October 2025 amendment brought all cell and gene therapy products under direct DCGI supervision — covering manufacturing, import, GMP compliance, and regulatory approval. This includes gene therapies (like BIRSA 101), stem cell products, and xenografts (animal tissue transplanted to humans). This was India's first comprehensive regulatory framework for these advanced therapies, signalling the country's readiness to enter the gene therapy era responsibly.
⚡ Quick Revision — Biotechnology Summary
| Topic | Key Facts |
|---|---|
| Methods | RDT: Isolate gene → insert into vector (plasmid) → transfer to host → express protein. PCR: Amplify DNA in vitro using primers + Taq polymerase (millions of copies). RNAi: Gene silencing via small RNAs. Tissue culture: Totipotency of plant cells. Bioinformatics: CS + biology for genomic data analysis. |
| CRISPR-Cas9 | From bacterial defence. Guide RNA + Cas9 protein. 2020 Nobel (Doudna & Charpentier). Next-gen: Base editing, Prime editing, TnpB (India, ICAR-CRRI). Ethical: germline editing, gene drives, He Jiankui scandal. Market: $2.87B (2025) → $12.22B (2035). |
| Applications | Red (medical): Gene therapy, CAR-T, genome sequencing, Humulin, Casgevy, BIRSA 101. White (industrial): Enzymes, biofuels. Green (agriculture): BT Cotton, genome-edited rice. Blue (environment): Bioremediation. Purple (animal): Dolly, transgenic animals. |
| India's Bioeconomy | $137 billion (2022). Target $300B by 2030. 4% GDP. 2M+ jobs. 6,756 startups. Top 12 globally, 3rd in Asia Pacific. Bio-industrials (43%) + Biopharma (36%) = 79% of bioeconomy. |
| Key Institutions | DBT (1986, nodal agency). BIRAC (startup support). NBTB (1982). NCMR (microbial resources). IBDC (data repository, FAIR principles). |
| Govt Initiatives | National Biopharma Mission (i3, BIRAC). Biotech-KISAN (2017, farm-level). Atal Jai Anusandhan. One Health Consortium (2021, zoonotic diseases). Biotech Parks. |
| Current Affairs 2025-26 | BIRSA 101: India's CRISPR sickle cell therapy (Nov 2025, CSIR-IGIB + SII). Genome-edited rice: DRR Rice 100 (Kamala) + Pusa DST Rice 1 (May 2025, ICAR, world first). TnpB patent (ICAR-CRRI). NextCAR19 CAR-T (350+ patients). Drug Rules amendment (Oct 2025, DCGI for gene therapy). CrisprBits Bengaluru centre (Jan 2025). Casgevy (first CRISPR drug, 2023). |
| Challenges | IP/patent barriers. Ethical: germline editing, designer babies. Environmental: gene drives, non-target species. Biosecurity: synthetic biology weapons. Regulatory gaps in developing countries. Liver toxicity in trials. |
🚨 5 UPSC Traps — Biotechnology:
Trap 1 — "Genome-edited crops = GM crops" → WRONG! Genome-edited crops (like India's CRISPR rice) do NOT contain foreign DNA. They use precise edits within the plant's own genome. GM crops (like BT Cotton) contain genes from a different organism (Bacillus thuringiensis). India's 2022 guidelines treat these differently — genome-edited plants (SDN-1/SDN-2) are exempt from strict GMO regulations.
Trap 2 — "Red Biotechnology = Industrial" → WRONG! Red = Medical/Pharmaceutical. White = Industrial. This is the most common swap trap. Remember: Red = Blood = Medicine. White = Clean = Industry.
Trap 3 — "PCR creates new genes" → WRONG! PCR amplifies (copies) existing DNA — it does NOT create new DNA or modify genes. It uses primers and Taq polymerase to make millions of copies of a specific DNA segment. Gene editing (CRISPR) modifies genes; PCR just copies them.
Trap 4 — "CRISPR can only be used in plants" → WRONG! CRISPR works on virtually any organism: bacteria, plants, animals, and humans. Casgevy (approved 2023) treats human blood diseases. India's BIRSA 101 targets human sickle cell mutation. CRISPR is used in agriculture, medicine, industry, and environmental science.
Trap 5 — "India has no indigenous gene-editing capability" → WRONG! India has developed: (1) BIRSA 101 — indigenous CRISPR therapy (CSIR-IGIB); (2) TnpB gene-editing tool — Indian patent (ICAR-CRRI); (3) World's first genome-edited rice (ICAR); (4) NextCAR19 — indigenous CAR-T therapy (ImmunoACT). India is rapidly building sovereign biotech capability.
Trap 1 — "Genome-edited crops = GM crops" → WRONG! Genome-edited crops (like India's CRISPR rice) do NOT contain foreign DNA. They use precise edits within the plant's own genome. GM crops (like BT Cotton) contain genes from a different organism (Bacillus thuringiensis). India's 2022 guidelines treat these differently — genome-edited plants (SDN-1/SDN-2) are exempt from strict GMO regulations.
Trap 2 — "Red Biotechnology = Industrial" → WRONG! Red = Medical/Pharmaceutical. White = Industrial. This is the most common swap trap. Remember: Red = Blood = Medicine. White = Clean = Industry.
Trap 3 — "PCR creates new genes" → WRONG! PCR amplifies (copies) existing DNA — it does NOT create new DNA or modify genes. It uses primers and Taq polymerase to make millions of copies of a specific DNA segment. Gene editing (CRISPR) modifies genes; PCR just copies them.
Trap 4 — "CRISPR can only be used in plants" → WRONG! CRISPR works on virtually any organism: bacteria, plants, animals, and humans. Casgevy (approved 2023) treats human blood diseases. India's BIRSA 101 targets human sickle cell mutation. CRISPR is used in agriculture, medicine, industry, and environmental science.
Trap 5 — "India has no indigenous gene-editing capability" → WRONG! India has developed: (1) BIRSA 101 — indigenous CRISPR therapy (CSIR-IGIB); (2) TnpB gene-editing tool — Indian patent (ICAR-CRRI); (3) World's first genome-edited rice (ICAR); (4) NextCAR19 — indigenous CAR-T therapy (ImmunoACT). India is rapidly building sovereign biotech capability.
